Shoji Mikio
Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.
Brain Nerve. 2012 May;64(5):497-504.
Recent advances in biomarker studies compiled from the Alzheimer's Disease Neuroimaging Initiative (ADNI) are summarized here. CSF Aβ42, total tau, and phosphorylated tau181 are the most sensitive biomarkers for diagnosing Alzheimer's disease (AD) and predicting the onset of AD in cases with mild cognitive impairment (MCI) due to AD. Many perspective studies on PiB-PET, FDG-PET, MRI volumetry, and some neuropsychiatric tests have provided evidence for the usefulness of these biomarkers for diagnosing AD and MCI due to AD. Basic and clinical studies have contributed considerably to the establishment of clinical evidence that supports the usefulness of these markers. Given the progress in the diagnosis of preclinical AD, discovery of therapy that is essential for the cure of AD is expected soon.
本文总结了从阿尔茨海默病神经影像倡议（ADNI）汇编的生物标志物研究的最新进展。脑脊液Aβ42、总tau蛋白和磷酸化tau181是诊断阿尔茨海默病（AD）以及预测由AD引起的轻度认知障碍（MCI）病例中AD发病的最敏感生物标志物。许多关于PiB-PET、FDG-PET、MRI容积测量和一些神经精神测试的前瞻性研究为这些生物标志物在诊断由AD引起的AD和MCI方面的有用性提供了证据。基础研究和临床研究为支持这些标志物有用性的临床证据的建立做出了重大贡献。鉴于临床前AD诊断方面的进展，预计很快就会发现对治愈AD至关重要的疗法。
